Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. [electronic resource]
Producer: 20170717Description: 1750-1756 p. digitalISSN:- 1468-201X
- Adult
- Aged
- Aged, 80 and over
- Cardiovascular Diseases -- diagnosis
- Cause of Death
- Chi-Square Distribution
- Databases, Factual
- Diabetes Mellitus, Type 2 -- diagnosis
- Electronic Health Records
- England -- epidemiology
- Erectile Dysfunction -- diagnosis
- General Practice
- Humans
- Kaplan-Meier Estimate
- Linear Models
- Logistic Models
- Male
- Middle Aged
- Multivariate Analysis
- Myocardial Infarction -- diagnosis
- Phosphodiesterase 5 Inhibitors -- therapeutic use
- Protective Factors
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.